Neurocrine biosciences inc
NBIX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
NBIX 近期報酬表現
-1.28%
Neurocrine biosciences inc
6.23%
同產業平均
1.02%
S&P500
與 NBIX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
APGE | Apogee therapeutics inc | - | 3 分 | 1 分 | 3 分 | 1 分 | |
ITCI | Intra-cellular therapies inc | 4 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
DCPH | Deciphera pharmaceuticals inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
LXEO | Lexeo therapeutics inc | - | 2 分 | 2 分 | 3 分 | 1 分 | |
EXEL | Exelixis, inc. | 4 分 | 4 分 | 2 分 | 2 分 | 1 分 |
- APGE Apogee therapeutics inc價值 -趨勢 3 分波段 1 分籌碼 3 分股利 1 分查看更多
NBIX 公司資訊
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.